Syneron Medical Ltd (ELOS) Tops Q4 EPS by 8c

Syneron Medical Ltd (NASDAQ: ELOS) reported Q4 EPS of $0.17, $0.08 better than the analyst estimate of $0.09. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $82.02 million.

Fourth Quarter 2016 Financial Highlights

• Revenue of $82.9 million, up 5.1% year-over-year
• Emerging products1 revenue of $22.6 million, which represents the Company\'s strategic growth drivers, grew 25.0% year-over-year
• Product revenue up 6.5% year-over-year; Aesthetic product revenue[2] up 11.0% year-over-year
• International product revenue grew 18.6% while North America declined 8.8% (North America Aesthetic product revenue2 declined 2.8%)
• APAC product revenue up 15.9% and EMEA product revenue up 19.8%
• Total Body Shaping revenue of $11.3 million grew 16.0% year-over-year
• GAAP net loss per share of $(0.03), compared to $0.05 net income per share in Q4 2015
• Non-GAAP net income per share of $0.14, compared to $0.07 net income per share in Q4 2015
• Cash position as of December 31, 2016 of $86.4 million with no debt; generated $6.2 million in cash flow from operations

For earnings history and earnings-related data on Syneron Medical Ltd (ELOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c